But the drug, an antibody that attacks the protein amyloid, does not work as well in people with more advanced disease.
An experimental drug can slow progression of Alzheimer’s disease in those who start taking it when the disease is still in its early stages. The drug, a monoclonal antibody called donanemab, does not improve symptoms. But among people who started taking it at the earliest stages of Alzheimer’s, 47% had no disease progression on some measures after one year, compared with 29% who took a placebo.
Read more: https://www.nature.com/articles/d41586-023-02321-1